Literature DB >> 10555902

Progression in psoriatic arthritis: role of time varying clinical indicators.

D D Gladman1, V T Farewell.   

Abstract

OBJECTIVE: We have shown that the presence of 5 or more effusions and high medication use at first clinic visit predicted clinical progression in patients with psoriatic arthritis (PsA), while a low erythrocyte sedimentation rate (ESR) was "protective." These clinical indicators will change over the course of a patient's disease. We investigated whether there is additional prognostic information available through monitoring these indicators at each clinic visit.
METHODS: A total of 365 patients with at least 2 followup visits at the PsA Clinic who did not have 10 or more damaged joints at first visit were included. Clinical assessments including the number of actively inflamed and damaged joints were carried out every 6-12 mo according to a standard protocol. The analysis used a generalized linear model that relates the number of damaged joints that developed between consecutive clinic visits to the information available at the first of the 2 visits, and in which the information was added to a baseline model including the first visit variables previously shown to be important.
RESULTS: Single factor analysis suggested that the addition of functional class, number of actively inflamed joints, and Lansbury index provide prognostic information for subsequent damage. The final multivariate model includes time varying information on the number of actively inflamed joints, functional class, and current damage, as well as first visit information on prior medication as predictive of progression of damage, plus male sex and a low ESR at first visit as "protective."
CONCLUSION: Time varying predictors for damage are important and should be monitored longitudinally in patients with PsA.

Entities:  

Mesh:

Year:  1999        PMID: 10555902

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  21 in total

Review 1.  Introduction/overview on clinical registries.

Authors:  D D Gladman; A Menter
Journal:  Ann Rheum Dis       Date:  2005-03       Impact factor: 19.103

Review 2.  Treat to target in psoriatic arthritis-evidence, target, research agenda.

Authors:  Laura C Coates; Philip S Helliwell
Journal:  Curr Rheumatol Rep       Date:  2015-06       Impact factor: 4.592

3.  Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised controlled trial.

Authors:  Laura C Coates; Anna R Moverley; Lucy McParland; Sarah Brown; Nuria Navarro-Coy; John L O'Dwyer; David M Meads; Paul Emery; Philip G Conaghan; Philip S Helliwell
Journal:  Lancet       Date:  2015-10-01       Impact factor: 79.321

4.  Receptor activator NF-kappaB ligand (RANKL) expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathy, osteoarthritis, and from normal patients: semiquantitative and quantitative analysis.

Authors:  T N Crotti; M D Smith; H Weedon; M J Ahern; D M Findlay; M Kraan; P P Tak; D R Haynes
Journal:  Ann Rheum Dis       Date:  2002-12       Impact factor: 19.103

Review 5.  Diagnosis and management of psoriatic arthritis.

Authors:  John Brockbank; Dafna Gladman
Journal:  Drugs       Date:  2002       Impact factor: 9.546

6.  [Psoriatric arthritis - a permanent challenge for rheumatologists and patients: part 2: imaging diagnostics, classification and therapy].

Authors:  S Finzel; M Englbrecht
Journal:  Z Rheumatol       Date:  2011-11       Impact factor: 1.372

7.  Clinical and radiological damage in psoriatic arthritis.

Authors:  F Siannis; V T Farewell; R J Cook; C T Schentag; D D Gladman
Journal:  Ann Rheum Dis       Date:  2005-08-26       Impact factor: 19.103

Review 8.  Psoriatic arthritis: epidemiology, clinical features, course, and outcome.

Authors:  D D Gladman; C Antoni; P Mease; D O Clegg; P Nash
Journal:  Ann Rheum Dis       Date:  2005-03       Impact factor: 19.103

Review 9.  Psoriatic arthritis clinical registries and genomics.

Authors:  D D Gladman; C Ritchlin; P S Helliwell
Journal:  Ann Rheum Dis       Date:  2005-03       Impact factor: 19.103

Review 10.  Advances in the management of psoriatic arthritis.

Authors:  Ignazio Olivieri; Salvatore D'Angelo; Carlo Palazzi; Angela Padula
Journal:  Nat Rev Rheumatol       Date:  2014-07-08       Impact factor: 20.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.